The U.S. ophthalmic market is worth $9.6 billion in 2006, up from $8.8 billion in 2005. At an average annual growth rate (AAGR) of 7.4%, the market will cross $13.8 billion in 2011.
Ophthalmic pharmaceuticals dominated the market throughout the forecast period. In 2006 pharmaceuticals comprised 46.6% of the market and, growing at an AAGR of 6.9%, will be worth more than $6.2 billion and maintain more than 45% of the market in 2011.
Contact lenses include both functional and cosmetic lenses. Contact lenses generate approximately $1.9 billion in revenues annually in the United States, accounting for a near 20% of the market.
Report Code: PHM031B, Published: September 2006, Analyst: Melissa Elder
INTRODUCTION
The aging of the population in the United States will result in a two-fold increase in the 65 and over population by 2030, a population that accounts for the highest incidence and prevalence of eye conditions and diseases. This sets the stage for increased research and development activities, speedy market approvals, and higher awareness through education. Additionally, current market competitors will endure pressure from the industry to continually provide advances in therapies and equipment and to compete with emerging competitors, who focus significantly on unmet needs of the ophthalmic consumer, including treatments for back of the eye conditions. The industry is likely to experience a burst of new products and heavy competition as the U.S. ophthalmic market advances.
This BCC Research report, U.S. Market for Prescription Ophthalmic Pharmaceuticals, Devices, Diagnostics and Surgical Equipment, provides a comprehensive description of conditions and diseases affecting the eye and products used for treatment. The study includes information regarding the incidence and prevalence of eye conditions and risk factors associated with those conditions. The major product segments presented with in-depth market and competitive analyses are ophthalmic prescription drugs, devices, diagnostics and surgical procedures. Research and development activities are included with an emphasis on segments offering benefits to aging populations.
SCOPE OF STUDY
This report contains:
A thorough evaluation of the U.S. prescription ophthalmic pharmaceutical, device, diagnostic, and surgical market, with forecasts to 2011
Market analysis focused on specific diseases and conditions such as cataract, glaucoma and refractive treatments
Information regarding incidence and prevalence of eye conditions and risk factors associated with those conditions
Examination of research and development activities with an emphasis on segments offering benefits to aging populations
Profiles of the major companies in the industry as well as a detailed patent analysis.
METHODOLOGY
The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key executives, product managers, and clinical specialists involved in the ophthalmic drug industry. Secondary methods included published literature in the area of ophthalmic drugs, investment reports, company literature, and various medical and business journals.
All market data pertains the U.S. market at the manufacturers' level. Data is expressed in current U.S. dollars. The base year of the report is 2006, with historical data provided for 2004 and 2005 and forecast data provided for 2011. Historical, base year, and forecast data is provided for each market segment of the report. Competitor market shares are provided for each market segment for the 2006 base year.
ANALYST CREDENTIALS
Melissa Elder is an experienced healthcare market analyst specializing in prescription and over-the-counter pharmaceuticals and various healthcare-related topics. Ms. Elder has worked in the healthcare field for the past 11 years and has a wide range of experience.
Report Code: PHM031B, Published: September 2006, Analyst: Melissa Elder
PHM27B The Clinical Trials Business - Updated Edition
